866-997-4948(US-Canada Toll Free)

Traumatic Brain Injury(TBI) - Pipeline Insights, 2017

Published By :


Published Date : Jul 2017

Category :


No. of Pages : 156 Pages

DelveInsights, Traumatic Brain Injury-Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this indication. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Traumatic Brain Injury. This report provides information on the therapeutic development based on the Traumatic Brain Injury dealing with all the pipeline drugs, comparative analysis of Traumatic Brain Injury at various stages covering Phase III, Phase II, Phase I, IND, Pre-clinical, and Discovery stages therapeutics assessment by monotherapy products and molecule type drug information. The report also covers the companys information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsights team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Pipeline Therapeutics
Therapeutics under Development by Companies
Late Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I and IND)
Pre-clinical and Discovery Products
Therapeutic Assessment: Active Products
Dormant Products
Discontinued Products
Comparative Analysis
Companies involved in Therapeutic Development
Consulting Services
About DelveInsight
Contact Us

List of Table

Table 1: Number of Products Under Development for Traumatic Brain Injury
Table 2: Number of Products under Development by Companies
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical Products
Table 7: Discovery Products
Table 8: Assessment by Monotherapy Products
Table 9: Assessment by Combination Therapy Products
Table 10: Assessment by Route Of Administration
Table 11:Assessment by Stage and Route Of Administration
Table 12: Assessment by Molecule Type
Table 13: Assessment by Stage and Molecule Type
Table 14: Dormant Products
Table 15: Discontinued Products
Table 16: American Life Science Pharmaceuticals (ALSP), Overview
Table 17: Anvyl LLC, Overview
Table 18: Apollo Endosurgery, Overview
Table 19: Aptinyx, Overview
Table 20: Astrocyte Pharmaceuticals Inc., Overview
Table 21: Athersys, Overview
Table Continued
Table 56: VG Life Sciences, Overview

List of Chart

Figure 1: Symptoms of Traumatic Brain Injury
Figure 2:Number of Products under Development for Traumatic Brain Injury,2017
Figure 3: Late Stage Products (Phase III)
Figure 4: Mid Stage Products (Phase II)
Figure 5: Early Stage Products (Phase I and IND)
Figure 6: Pre-clinical and Discovery Products
Figure 7: Assessment by Monotherapy Products
Figure 8: Assessment by Combination Therapy Products
Figure 9: Assessment by Route of Administration
Figure 10: Assessment by Stage and Route of Administration
Figure 11: Assessment by Molecule Type
Figure 12: Assessment by Stage and Molecule Type
Figure 13: Dormant Products
Figure 14: Discontinued Products

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *